- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01639820
Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts (SENTICOL2)
Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Randomized Multicenter Study With Evaluation of Medico-economic Impacts
Patients with early cervical cancer are usually treated with radical hysterectomy + pelvic lymph-node dissection. The study randomizes patients in 2 arms. The control arm is the classical surgical treatment including identification of the sentinel nodes, full pelvic lymph-node dissection and radical hysterectomy.
The experimental arm is only sentinel node identification + radical hysterectomy.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69677
- Service de Gynécologie, Hôpital Femme Mère Enfant
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women 18 years of age or older,
- Absence of contraindication to laparoscopy,
- Uterine cervical carcinoma (every histological type except neuroendocrine),
- Stage IA1 with lymphatic tumor space involvement (LVSI) or IA2 diagnosed on cervical conization; or stage IA2, IB1 or IIA detected by clinical examination, confirmed by biopsy and measured by the MRI, the highest diameter being lower to 4 cm (a preoperative brachytherapy is allowed for tumors 2 to 4 cm in diameter),
- Negative pregnancy test for women able to procreate,
- Having the French National Social Security
- Signed informed consent
Exclusion Criteria:
- Neuroendocrine carcinoma,
- In situ carcinoma or stage IA1 without LVSI,
- Maximal tumoral diameter measured by MRI more than 4 cm,
- Stage IB1 by "down-staging",
- Stage IB2, IIB to IVB, including those who had a response to neoadjuvant treatment (chemotherapy or RT + chemotherapy) ,
- Presence of distant metastases,
- Progression of the cervical cancer or recurrence,
- History of pelvic lymphadenectomy,
- Other cancer diagnosed during the course of treatment,
- Contraindication to the injected products : allergy known to Patent Blue or rhenium sulfide,
- History of severe allergy (history of Quincke's edema, anaphylactic shock),
- Patient who does not understand, speak or write the French language,
- Pregnant woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Strategy A
Only identification of sentinel nodes (without pelvic lymph-node dissection)
|
only identification of sentinel nodes (without pelvic lymph-node dissection)
|
Other: Strategy B
Identification of sentinel nodes + full pelvic lymph-node dissection
|
identification of sentinel nodes + full pelvic lymph-node dissection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with complications observed in the 2 arms during the per and post-operative period up to 6 months
Time Frame: 6 months after surgery
|
6 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Score of the questionnaire of quality of life at 30 days, 3 months and 6 months after surgery
Time Frame: 30 days, 3 months and 6 months after surgery
|
30 days, 3 months and 6 months after surgery
|
the costs of both studied strategies
Time Frame: At the surgery until 6 months
|
At the surgery until 6 months
|
the detection rate of the sentinel node technique in the 2 arms
Time Frame: Day 1
|
Day 1
|
the false negative rate in the control arm
Time Frame: Day 1
|
Day 1
|
the sites of recurrence for each strategy
Time Frame: Day 1
|
Day 1
|
Number of patients without 3 years-recurrence for each strategy
Time Frame: 3 years after surgery
|
3 years after surgery
|
Number of patient treated by radio chemotherapy because of the presence of micrometastases in the sentinel node
Time Frame: 30 days, 3 months and 6 months after surgery
|
30 days, 3 months and 6 months after surgery
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Precancerous Conditions
- Carcinoma in Situ
- Uterine Cervical Neoplasms
- Cervical Intraepithelial Neoplasia
- Uterine Cervical Dysplasia
Other Study ID Numbers
- 2008.515
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Dysplasia
-
University of Mississippi Medical CenterNot yet recruitingCervical Dysplasia, Uterine | Vaginal Dysplasia | Vulvar Dysplasia
-
Sunnybrook Health Sciences CentreCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteJames and Esther King Biomedical Research ProgramRecruitingSmoking Cessation | Cervical Cancer | High Grade Cervical DysplasiaUnited States
-
University of AarhusNot yet recruitingCervical Cancer
-
NHS Greater Glasgow and ClydeUnknownCervical Carcinoma | Cervical Dysplasia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
William Marsh Rice UniversityM.D. Anderson Cancer Center; Albert Einstein College of Medicine; The Cleveland... and other collaboratorsCompleted
-
Ruhr University of BochumCompletedUterine Cervical DysplasiaGermany
-
Sarah HufCompletedCervical Carcinoma | Cervical DysplasiaUnited Kingdom
-
University of CopenhagenDanish Cancer SocietyUnknown
Clinical Trials on only identification of sentinel nodes (without pelvic lymph-node dissection)
-
Charles University, Czech RepublicCompletedCervical CancerCzechia
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage I Uterine Corpus Cancer AJCC v8United States
-
National Cancer Center, KoreaRecruitingBreast Neoplasm | Neoadjuvant Therapy | Sentinel Lymph Node BiopsyKorea, Republic of
-
Parc de Salut MarGEICAMRecruiting
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingCervical Cancer | Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Lymph Node Disease | Lymph Node Metastases | Sentinel Lymph Node Biopsy | Endometrium Tumor | Cervical Neoplasm | Micrometastasis | Cervical TumorItaly
-
Umraniye Education and Research HospitalUnknownThyroid Neoplasms | Sentinel Lymph Node | Thyroid Cancer | Lymph Node Metastases | Thyroid Carcinoma, Papillary | Thyroid MetastasesTurkey
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBreast Cancer LymphedemaUnited States
-
National Cancer Center, ChinaNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast... and other conditionsUnited States